Basiliximab in a Triple-Drug Regimen With Tacrolimus and Steroids in Liver Transplantation

Gruttadauria, Salvatore; Vasta, F.; Mandalà, Lucio; Cintorino, Davide; Piazza, Tommaso; Spada, Marco; Verzaro, Roberto; Gridelli, Bruno

doi:10.1016/j.transproceed.2005.06.063

Cited by 38 publications

(21 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of ACR has decreased with improvements in immunosuppressive medications, although it still affects 15-25% of recipients [32,33]. Steroid pulse therapy, the standard treatment for ACR, is associated with significant complications, especially in patients with HCV [34][35][36].…”

Section: Discussionmentioning

confidence: 99%

Association of interleukin4 gene polymorphisms of recipients and donors with acute rejection following living donor liver transplantation

Kamei

Masuda

Ishigami

et al. 2016

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Association of interleukin4 gene polymorphisms of recipients and donors with acute rejection following living donor liver transplantation

Kamei

Masuda

Ishigami

et al. 2016

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

“…Induction therapy with anti-lymphocyte antibodies such as OKT-3 (anti-CD3 antibody) or anti-thymocyte globulin has been reported to increase the risk of HCC recurrence 22. Although in previous reports, basiliximab induction in combination with tacrolimus-based immunosuppressive regimens did not increase the risk of post-transplant lymphoproliferative disease, the direct impact of basiliximab on HCC recurrence has not been investigated 23,24,25. In a study conducted by Ramirez et al, three (18%) recipients with HCC developed and died of metastatic HCC in the basiliximab group compared with none in the placebo group, not statistically significant 22.…”

Section: Discussionmentioning

confidence: 99%

Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation

Lee

Kim

et al. 2014

Clin Mol Hepatol

View full text Add to dashboard Cite

Background/AimsThe most commonly used immunosuppressant therapy after liver transplantation (LT) is a combination of tacrolimus and steroid. Basiliximab induction has recently been introduced; however, the most appropriate immunosuppression for hepatocellular carcinoma (HCC) patients after LT is still debated.MethodsNinety-three LT recipients with HCC who took tacrolimus and steroids as major immunosuppressants were included. Induction with basiliximab was implemented in 43 patients (46.2%). Mycophenolate mofetil (MMF) was added to reduce the tacrolimus dosage (n=28, 30.1%). The 1-year tacrolimus exposure level was 7.2 ± 1.3 ng/mL (mean ± SD).ResultsThe 1- and 3-year recurrence rates of HCC were 12.9% and 19.4%, respectively. Tacrolimus exposure, cumulative steroid dosages, and MMF dosages had no impact on HCC recurrence. Induction therapy with basiliximab, high alpha fetoprotein (AFP; >400 ng/mL) and protein induced by vitamin K absence/antagonist-II (PIVKA-II; >100 mAU/mL) levels, and microvascular invasion were significant risk factors for 1-year recurrence (P<0.05). High AFP and PIVKA-II levels, and positive 18fluoro-2-deoxy-d-glucose positron-emission tomography findings were significantly associated with 3-year recurrence (P<0.05).ConclusionsInduction therapy with basiliximab, a strong immunosuppressant, may have a negative impact with respect to early HCC recurrence (i.e., within 1 year) in high-risk patients.

show abstract

“…More importantly, among renal transplant recipients receiving graft-rejection prophylaxis with cyclosporine, azathioprine, and corticosteroids with or without additional basiliximab, no difference was seen in the incidence of opportunistic infections, but a signifi cantly lower rate of acute graft failure was reported in the basiliximabtreated patient group [27]. In patients undergoing liver transplantation, the risk of IFI did not increase with use of the IL-2 receptor antibody in combination with tacrolimus and corticosteroids [28].…”

Section: Il-2 Receptor Antibody (Anti-cd25) Basiliximabmentioning

confidence: 93%

New immunosuppressive agents and risk for invasive fungal infections

Maschmeyer

Patterson²

2009

Curr Infect Dis Rep

View full text Add to dashboard Cite

Increased numbers of invasive fungal infections (IFI) were reported in patients treated with newer immunosuppressive drugs such as tumor necrosis factor (TNF)-alpha antagonists, the anti-CD52 antibody alemtuzumab, or the interleukin-2 receptor antibody basiliximab. These drugs are administered to patients who have autoimmune inflammatory diseases and lymphoid malignancies, or are recipients of solid organ or allogeneic hematopoietic stem cell transplants. IFI risk is higher in patients receiving TNF-alpha blockers or alemtuzumab late in the course of disease and in those with a history of IFI. Incidence and mortality rates of IFI are confounded by frequent, multiple comedications, heterogeneous definitions for IFI, and a presumed reporting bias. For filamentous molds and endemic fungal infections, different regional prevalence rates must be considered. Generally, invasive infections are more frequent among these groups and thus are important considerations in the management of patients receiving these immunosuppressive drugs.

show abstract

Basiliximab in a Triple-Drug Regimen With Tacrolimus and Steroids in Liver Transplantation

Cited by 38 publications

References 7 publications

Association of interleukin4 gene polymorphisms of recipients and donors with acute rejection following living donor liver transplantation

Association of interleukin4 gene polymorphisms of recipients and donors with acute rejection following living donor liver transplantation

Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation

New immunosuppressive agents and risk for invasive fungal infections

Contact Info

Product

Resources

About